RALLYBIO CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
RALLYBIO CORPORATION (RLYB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 11.40 thousand shares for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-26
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 11.40K shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was -361.26K shares, a 1651.88% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 266.51K shares, a 262.14% increase year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 653.11K shares, a 183.36% increase from fiscal 2023.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 230.48K shares, a 25.84% increase from fiscal 2022.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 183.15K shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | 11.40K shares S-4/A · filed 2026-08-26 | -349.86K shares derived: sum of 3 quarters · filed 2026-08-26 | -83.34K shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | 11.40K shares S-4 · filed 2026-07-15 | -349.86K shares derived: sum of 2 quarters · filed 2026-08-26 | -83.34K shares derived: sum of 3 quarters · filed 2026-08-26 | 63.16K shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | -361.26K shares derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -94.75K shares derived: sum of 2 quarters · filed 2026-08-26 | 51.76K shares derived: sum of 3 quarters · filed 2026-08-26 | 51.76K shares S-4/A · filed 2026-08-26 |
| 2025-09-30 | 266.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 413.02K shares derived: sum of 2 quarters · filed 2025-11-06 | 413.02K shares 10-Q · filed 2025-11-06 | 436.30K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 146.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 146.51K shares 10-Q · filed 2025-08-07 | 169.78K shares derived: sum of 3 quarters · filed 2025-08-07 | 243.38K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 23.28K shares derived: sum of 2 quarters · filed 2025-05-08 | 96.87K shares derived: sum of 3 quarters · filed 2025-05-08 | 225.69K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 23.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 96.87K shares derived: sum of 2 quarters · filed 2025-03-13 | 225.69K shares derived: sum of 3 quarters · filed 2025-03-13 | 653.11K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 73.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 202.41K shares derived: sum of 2 quarters · filed 2024-11-07 | 629.83K shares 10-Q · filed 2024-11-07 | 674.32K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 128.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 556.24K shares 10-Q · filed 2024-08-08 | 600.73K shares derived: sum of 3 quarters · filed 2024-08-08 | 640.22K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 427.42K shares 10-Q · filed 2024-05-09 | 471.92K shares derived: sum of 2 quarters · filed 2024-05-09 | 511.40K shares derived: sum of 3 quarters · filed 2024-05-09 | 511.40K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 44.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 83.98K shares derived: sum of 2 quarters · filed 2024-03-12 | 83.98K shares derived: sum of 3 quarters · filed 2024-03-12 | 230.48K shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 39.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 39.49K shares derived: sum of 2 quarters · filed 2023-11-09 | 185.99K shares 10-Q · filed 2023-11-09 | 310.33K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 146.50K shares 10-Q · filed 2023-08-08 | 270.84K shares derived: sum of 3 quarters · filed 2023-08-08 | 325.62K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 146.50K shares 10-Q · filed 2023-05-09 | 270.84K shares derived: sum of 2 quarters · filed 2023-05-09 | 325.62K shares derived: sum of 3 quarters · filed 2023-05-09 | 329.65K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 124.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 179.12K shares derived: sum of 2 quarters · filed 2023-03-06 | 183.15K shares derived: sum of 3 quarters · filed 2023-03-06 | 183.15K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 54.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 58.81K shares derived: sum of 2 quarters · filed 2022-11-07 | 58.81K shares 10-Q · filed 2022-11-07 | |
| 2022-06-30 | 4.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 4.03K shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-15 | |||
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |